Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
The best next step is speaking with a qualified medical provider who understands both medical weight loss and peptide-based wellness approaches
It is essential to discuss any concerns with them before starting treatment
25 mg/day oral Tirzepatide 15 mg/week Retatrutide 12 mg/week Liraglutide 3.0 mg/day Factor Peak trial weight loss Semaglutide -14.9% at 68 wks (STEP 1) Tirzepatide -22.5% at 72 wks (SURMOUNT-1) Retatrutide -28.7% at 68 wks (TRIUMPH-4) Liraglutide -8% at 56 wks (SCALE) Factor FDA status (June 2026) Semaglutide Approved (T2D, obesity, CVD, MASH, CKD, oral) Tirzepatide Approved (T2D, obesity) Retatrutide Investigational - Phase 3 Liraglutide Approved (Saxenda obesity, Victoza T2D) Factor CV outcomes data Semaglutide Yes - SELECT (20% MACE drop) Tirzepatide SURPASS-CVOT ongoing Retatrutide TRIUMPH-3 ongoing Liraglutide Yes - LEADER (13% MACE drop) These compounds are not interchangeable
Note that no brain amyloid PET or tau PET (for eligibility or pharmacodynamics) were performed in the Evoke and Evoke+ trials
Send Press Release
Although HCG is more accessible and affordable, its results are less consistent and generally less impressive in terms of long-term weight management
US$ 20.18
US$ 21.83
US$ 23.91
US$ 22.75
